Autres langues Nanobiotix

Actions

NANO

FR0011341205

Marché Fermé - Euronext Paris Autres places de cotation 17:35:25 25/04/2024			Pré-ouverture 07:38:48
5,4 ^EUR	-2,44 %		5,445	+0,83 %

25/04	Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024
25/04	Nanobiotix : 75,3 millions d’euros de trésorerie, visibilité jusqu’au troisième trimestre 2025	AO

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bolsa de Italia: Il mercato è un po' impazzito	25/04
Bolsa de Madrid: El mercado se está volviendo un poco loco	25/04
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results	24/04
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	24/04
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	24/04
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024	17/04
Nanobiotix : partie escalade achevée pour l'étude 2020-0123	03/04
Bolsa de Madrid: Después de Semana Santa, algo va mal	03/04
Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer	02/04
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation	02/04
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommends Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation	02/04
Nanobiotix to Present at Upcoming Investor Conferences in March	06/03
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference	31/01
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference	31/01
Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug	30/01
Bolsa de Madrid: China despierta, y luego no despierta	30/01
Nanobiotix : atteinte d'objectifs pour NANORAY-312	30/01
Nanobiotix Gets $20 Million Milestone Payment from Janssen	30/01
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study	29/01
Nanobiotix : transfert de droits sur NBTXR3 en Asie	27/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Nanobiotix

Actions

NANO

FR0011341205

Autres langues

Filtres